|
Adult Glioblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
By multivariate analysis, we found that a younger age and MGMT promoter methylation were significant favorable factors in patients with glioblastoma.
|
19730774 |
2009 |
|
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status.
|
19514084 |
2009 |
|
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings suggest that immunohistochemical analysis of O(6)-MGMT in patients with glioblastoma can be a useful method to predict the effects of chemotherapy and identify alternative chemotherapeutic regimens for O(6)-MGMT-positive patients.
|
19019175 |
2009 |
|
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Methylation of the CpG island in the MGMT promoter region is a frequent event in several cancer types including colorectal cancer, lung cancer, lymphoma, and glioblastoma.
|
19789298 |
2009 |
|
Adult Glioblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Methylation status of the MGMT gene promoter fails to predict the clinical outcome of glioblastoma patients treated with ACNU plus cisplatin.
|
19170894 |
2009 |
|
Adult Glioblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
The biologic effect of MGMT promoter methylation or pathogenetic features associated with MGMT promoter methylation may be different for AOT compared with glioblastoma.
|
19901104 |
2009 |
|
Adult Glioblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
These results suggested that epigenetic inactivation of MGMT plays an important role in the survival of glioblastoma patients and this inactivated gene involved in p53 mutation.
|
19544111 |
2009 |
|
Adult Glioblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
By Cox multivariate analysis, tumour grade and MGMT promoter methylation correlated with time to progression (p<0.05); MGMT promoter methylation correlated with superior overall survival in AA/AOA but not in glioblastoma.
|
18945611 |
2009 |
|
Adult Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The results of the present study suggest that MGMT promoter methylation in combination with negative MGMT expression might be a good prognostic factor in patients with glioblastoma.
|
19834398 |
2009 |
|
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
MGMT gene silencing and benefit from temozolomide in glioblastoma.N Engl J Med 2005;352:997-1003].
|
18973931 |
2009 |
|
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prolonged and severe thrombocytopenia with pancytopenia induced by radiation-combined temozolomide therapy in a patient with newly diagnosed glioblastoma--analysis of O6-methylguanine-DNA methyltransferase status.
|
19037596 |
2009 |
|
Adult Glioblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
After irradiation and exposure to steroid and temozolomide 6 and 24 h later, a methylated MGMT promoter and negative protein expression were seen in U343 glioblastoma cell lines which have methylated promoter and negative protein expression.
|
20372840 |
2010 |
|
Adult Glioblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Moreover, in the absence of potent alternative drugs, temozolomide chemotherapy should not be withheld from patients with newly diagnosed glioblastoma without MGMT promoter methylation in general practice.
|
20919826 |
2010 |
|
Adult Glioblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
The assessment of the MGMT promoter methylation status has become of clinical relevance as a molecular marker associated with response to alkylating chemotherapy and prolonged survival of glioblastoma patients.
|
20725792 |
2010 |
|
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
MGMT promoter methylation is the key mechanism of MGMT gene silencing and predicts a favorable outcome in patients with glioblastoma who are exposed to alkylating agent chemotherapy.
|
19997073 |
2010 |
|
Adult Glioblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
An analysis of image texture, tumor location, and MGMT promoter methylation in glioblastoma using magnetic resonance imaging.
|
19796694 |
2010 |
|
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
There is a growing body of evidence that deficiency of DNA mismatch repair proteins other than O(6)-methylguanine-DNA methyltransferase (MGMT) also contributes to glioblastoma recurrence.
|
20223108 |
2010 |
|
Adult Glioblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Prognostic value of MGMT promoter methylation in glioblastoma patients treated with temozolomide-based chemoradiation: a Portuguese multicentre study.
|
20428822 |
2010 |
|
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have thus shown an in vitro link between phosphoinositide 3-kinase-mediated HOXA9/HOXA10 expression, and a drug-resistant, progenitor cell phenotype in MGMT-independent pediatric glioblastoma.
|
20935218 |
2010 |
|
Adult Glioblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
MGMT promoter methylation is the only potentially predictive marker, at least for alkylating agent chemotherapy in glioblastoma.
|
20862485 |
2010 |
|
Adult Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Low MGMT expression and MGMT promoter methylation are both predictive markers for slower tumor progression in patients with glioblastoma.
|
20232102 |
2010 |
|
Adult Glioblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
These results confirm the prognostic value of MGMT promoter methylation in glioblastoma patients initially treated with TMZ.
|
19841865 |
2010 |
|
Adult Glioblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Promoter methylation analysis of O6-methylguanine-DNA methyltransferase in glioblastoma: detection by locked nucleic acid based quantitative PCR using an imprinted gene (SNURF) as a reference.
|
20167086 |
2010 |
|
Adult Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Intratumoral hypoxic gradient drives stem cells distribution and MGMT expression in glioblastoma.
|
20309962 |
2010 |
|
Adult Glioblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma.
|
20150378 |
2010 |